Databases in the area of pharmacogenetics

Human Mutation

Volumn 32, Issue 5, 2011, Pages 526-531

  Sim, Sarah C ^a   Altman, Russ B ^b   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Stanford University   (United States)

Author keywords

Adverse drug reaction; Cytochrome P450; Database; Personalized medicine; Pharmacogenetics; Polymorphism; Transporter

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ARYLAMINE ACETYLTRANSFERASE; BIOLOGICAL MARKER; CYTOCHROME P450; CYTOCHROME P450 2D6; GLUCURONOSYLTRANSFERASE; PREGNANE X RECEPTOR; SMALL NUCLEAR RNA;

ALLELE; DATA BASE; DRUG METABOLISM; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INFORMATION PROCESSING; MEDICAL LITERATURE; MEDLINE; NATIONAL HEALTH ORGANIZATION; NOMENCLATURE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

DATABASES, FACTUAL; DRUG TOXICITY; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 79955008129     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21454     Document Type: Review

References (41)

1. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, Dudley JT, Ormond KE, Pavlovic A, Morgan AA, Pushkarev D, Neff NF, Hudgins L, Gong L, Hodges LM, Berlin DS, Thorn CF, Sangkuhl K, Hebert JM, Woon M, Sagreiya H, Whaley R, Knowles JW, Chou MF, Thakuria JV, Rosenbaum AM, Zaranek AW, Church GM, Greely HT, Quake SR, Altman RB. 2010. Clinical assessment incorporating a personal genome. Lancet 375:1525-1535.
2. Bertz RJ, Granneman GR. 1997. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
3. Coulet A, Shah NH, Garten Y, Musen M, Altman RB. 2010. Using text to build semantic networks for pharmacogenomics. J Biomed Inform Aug 17 [Epub ahead of print].
4. Daly AK. 2010. Drug-induced liver injury: past, present and future. Pharmacogenomics 11:607-611.
5. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. 2009. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4:e4439.
6. Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. 2010. Emergency re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol 70:749-755.
7. Eichelbaum M, Altman RB, Ratain M, Klein TE. 2009. New feature: pathways and important genes from PharmGKB. Pharmacogenet Genomics 19:403.
8. Eichelbaum M, Ingelman-Sundberg M, Evans WE. 2006. Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119-137.
9. Evans WE, Relling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487-491.
10. Garten Y, Altman RB. 2009. Pharmspresso: a text mining tool for extraction of pharmacogenomic concepts and relationships from full text. BMC Bioinformatics 10(Suppl 2):S6.
11. Garten Y, Altman RB. 2010. Teaching computers to read the pharmacogenomics literature...so you don't have to. Pharmacogenomics 11:515-518.
12. Garten Y, Tatonetti NP, Altman RB. 2010. Improving the prediction of pharmacogenes using text-derived drug-gene relationships. Pac Symp Biocomput 305-314.
13. Hansen NT, Brunak S, Altman RB. 2009. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 86:183-189.
14. Hein DW, Boukouvala S, Grant DM, Minchin RF, Sim E. 2008. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics 18:367-368.
15. Hein DW, Grant DM, Sim E. 2000. Update on consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenetics 10:291-292.
16. Ingelman-Sundberg M. 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25:193-200.
17. Ingelman-Sundberg M, Oscarson M. 2002. Human CYP allele database: submission criteria procedures and objectives. Methods Enzymol 357:28-36.
18. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. 2007. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
19. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmoller J. 2004. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473.
20. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA; International Warfarin Pharmacogenetics Consortium. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764.
21. Kroetz DL, Yee SW, Giacomini KM. 2010. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther 87:109-116.
22. Lazarou J, Pomeranz BH, Corey PN. 1998. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205.
23. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, Chen CH, Motsinger-Reif A, Sagreiya H, Liu N, Wu AH, Gage BF, Jorgensen A, Pirmohamed M, Shin JG, Suarez-Kurtz G, Kimmel SE, Johnson JA, Klein TE, Wagner MJ; International Warfarin Pharmacogenetics Consortium. 2010. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:3827-3934.
24. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW. 2005. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
25. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. 2010. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830.
26. Mi H, Thomas PD, Ring HZ, Jiang R, Sangkuhl K, Klein TE, Altman RB. 2010. PharmGKB summary: dopamine receptor D2. Pharmacogenet Genomics Aug 23 [Epub ahead of print].
27. Moore TJ, Cohen MR, Furberg CD. 2007. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 167:1752-1759.
28. Oscarson M, Ingelman-Sundberg M. 2002. CYPalleles: a web page for nomenclature of human cytochrome P450 alleles. Drug Metab Pharmacokinet 17:491-495.
29. Ozawa N, Shimizu T, Morita R, Yokono Y, Ochiai T, Munesada K, Ohashi A, Aida Y, Hama Y, Taki K, Maeda K, Kusuhara H, Sugiyama Y. 2004. Transporter database, TP-Search: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm Res 21:2133-2134.
30. Paul E, End-Rodrigues T, Thylen P, Bergman U. 2008. Adverse drug reactions a common cause of hospitalization of the elderly. A clinical retrospective study. Lakartidningen 105:2338-2342.
31. Pirmohamed M, Park BK. 2001. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22:298-305.
32. Sangkuhl K, Shuldiner AR, Klein TE, Altman RB. 2010. Platelet aggregation pathway. Pharmacogenet Genomics Oct 8 [Epub ahead of print].
33. Sim E, Lack N, Wang CJ, Long H, Westwood I, Fullam E, Kawamura A. 2008. Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 254:170-183.
34. Sim SC, Ingelman-Sundberg M. 2006. The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods Mol Biol 320:183-191.
35. Sim SC, Ingelman-Sundberg M. 2010. The Human Cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 4:278-281.
36. Sim SC, Ingelman-Sundberg M. 2011. Pharmacogenetic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci Dec 22 [Epub ahead of print].
37. Sim SC, Miller WL, Zhong XB, Arlt W, Ogata T, Ding X, Wolf CR, Flück CE, Pandey AV, Henderson CJ, Porter TD, Daly AK, Nebert DW, Ingelman-Sundberg M. 2009. Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenet Genomics 19:565-566.
38. Spear BB, Heath-Chiozzi M, Huff J. 2001. Clinical application of pharmacogenetics. Trends Mol Med 7:201-204.
39. Tatonetti NP, Liu T, Altman RB. 2009. Predicting drug side-effects by chemical systems biology. Genome Biol 10:238.
40. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV. 1995. Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17.
41. Weinshilboum R. 2003. Inheritance and drug response. N Engl J Med 348:529-537.